Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MDGL
SellHot AirMadrigal Pharmaceuticals, Inc. · Healthcare · United States · $12.3B · Avg Vol: $179M/d
COMPANY DESCRIPTION
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for non-alcoholic steatohepatitis (NASH) and other liver diseases. Its lead product candidate, resmetirom, targets the thyroid hormone receptor beta, addressing an area with significant unmet medical need and no approved treatments. The company's competitive edge lies in its potential first-in-class NASH therapy, which could capture a substantial share of this growing market if approved, offering a significant opportunity in a challenging disease area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 180.1M | 958.4M | 432.1% | 1.3B | 1.5B | 2.1B | 49.6% |
| EPS | -17.23 | -19.99 | -21.90 | -12.85 | — | -14.00 | -6.49 | 9.63 | — |
| Shares | 18.1M | 19.9M | 22.0M | 22.8M | +26.2% | 23.1M | — | — | — |
| Debt | 49.9M | 117.2M | 119.6M | 347.6M | 91.0% | 347.8M | — | — | — |
| Equity | 197.4M | 405.3M | 754.4M | 602.7M | 45.1% | — | — | — | — |
| Op CF | -224.9M | -324.2M | -455.6M | -189.6M | — | -197.7M | — | — | — |
| Inv CF | 206.7M | -502.5M | -274.4M | 32.3M | — | — | — | — | — |
| Fin CF | 313.5M | 595.1M | 735.1M | 256.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDGL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals, Inc.(you) | $12.3B | 31 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 31 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 26 | Sell |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 32 | Sell |
| BBIO | BridgeBio Pharma, Inc. | $15.0B | 26 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 25 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 33 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%